Exploring the role of monocarboxylate transporter 4 in diverse KRAS mutation subtypes of colorectal Cancer.

ABSTRACT: This study explored the therapeutic potential of monocarboxylate transporter 4 (MCT4/SLC16A3) in KRAS-mutant colorectal cancer (CRC). By integrating immunohistochemistry with UCSC Xena database analysis, we identified a distinct MCT4 expression pattern in KRAS-mutant CRC. Cytoplasmic MCT4 expression was positively correlated with KRAS mutation status and mismatch repair (MMR) proficiency, but negatively associated with sex and tumor differentiation. Plasma membranous MCT4 expression was also positively correlated with KRAS mutations and negatively with differentiation grade. Notably, tumors harboring KRAS codon 13 mutations, particularly G13D, showed higher MCT4 expression than those with codon 12 mutations, such as G12D. Kaplan-Meier survival analysis revealed a significant association be

SUBMITTER: Gong Q 

PROVIDER: S-EPMC12223049 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature